

RESEARCH ARTICLES



- 879**  **Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention**
Nagi B. Kumar, Julio Pow-Sang, Kathleen M. Egan, Philippe E. Spiess, Shohreh Dickinson, Raoul Salup, Mohamed Helal, Jerry McLarty, Christopher R. Williams, Fred Schreiber, Howard L. Parnes, Said Sebti, Aslam Kazi, Loveleen Kang, Gwen Quinn, Tiffany Smith, Binglin Yue, Karen Diaz, Ganna Chornokur, Theresa Crocker, and Michael J. Schell
- 888**  **Effect of Metformin on Breast Ductal Carcinoma *In Situ* Proliferation in a Randomized Presurgical Trial**
Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Massimiliano Cazzaniga, Davide Serrano, Matteo Lazzeroni, Andrea Vingiani, Oreste Gentilini, Marilena Petrerá, Giuseppe Viale, Jack Cuzick, Bernardo Bonanni, and Giancarlo Prunerí
- 895** **Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model**
Sarah A. Mazzilli, Pamela A. Hershberger, Mary E. Reid, Paul N. Bogner, Kristopher Atwood, Donald L. Trump, and Candace S. Johnson
- 905** **Physical Activity from Early Adulthood and Risk of Prostate Cancer: A 24-Year Follow-Up Study among Icelandic Men**
Soffia M. Hrafnkelsdóttir, Jóhanna E. Torfadóttir, Thor Aspelund, Kristjan T. Magnusson, Laufey Tryggvadóttir, Vilmondur Gudnason, Lorelei A. Mucci, Meir Stampfer, and Unnur A. Valdimarsdóttir
- 912** **Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women**
Carol J. Fabian, Bruce F. Kimler, Teresa A. Phillips, Jessica A. Box, Amy L. Kreutzjans, Susan E. Carlson, Brandon H. Hidaka, Trina Metheny, Carola M. Zalles, Gordon B. Mills, Kandy R. Powers, Debra K. Sullivan, Brian K. Petroff, Whitney L. Hensing, Brooke L. Fridley, and Stephen D. Hursting
See related article, p. 922
- 922** **Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women**
Carol J. Fabian, Bruce F. Kimler, Teresa A. Phillips, Jennifer L. Nydegger, Amy L. Kreutzjans, Susan E. Carlson, Brandon H. Hidaka, Trina Metheny, Carola M. Zalles, Gordon B. Mills, Kandy R. Powers, Debra K. Sullivan, Brian K. Petroff, Whitney L. Hensing, Brooke L. Fridley, and Stephen D. Hursting
See related article, p. 912
- 932** **Robust *In Vitro* and *In Vivo* Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine**
Hanna Seitz, Lis Ribeiro-Müller, Elena Canali, Angelo Bolchi, Massimo Tommasino, Simone Ottonello, and Martin Müller
- 942** **Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density**
Anna H. Wu, Darcy Spicer, Agustin Garcia, Chiu-Chen Tseng, Linda Hovanessian-Larsen, Pulin Sheth, Sue Ellen Martin, Debra Hawes, Christy Russell, Heather MacDonald, Debu Tripathy, Min-Ying Su, Giske Ursin, and Malcolm C. Pike
- 952** **Colon Tumors with the Simultaneous Induction of Driver Mutations in *APC*, *KRAS*, and *PIK3CA* Still Progress through the Adenoma-to-carcinoma Sequence**
Jamie N. Hadac, Alyssa A. Leystra, Terrah J. Paul Olson, Molly E. Maher, Susan N. Payne, Alexander E. Yueh, Alexander R. Schwartz, Dawn M. Albrecht, Linda Clipson, Cheri A. Pasch, Kristina A. Matkowskyj, Richard B. Halberg, and Dustin A. Deming
- 962** **Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study**
Erin L. Van Blarigan, John P. Gerstenberger, Stacey A. Kenfield, Edward L. Giovannucci, Meir J. Stampfer, Lee W. Jones, Steven K. Clinton, June M. Chan, and Lorelei A. Mucci
- 968**  **Low SFRP1 Expression Correlates with Poor Prognosis and Promotes Cell Invasion by Activating the Wnt/ β -Catenin Signaling Pathway in NPC**
Xian-Yue Ren, Guan-Qun Zhou, Wei Jiang, Ying Sun, Ya-Fei Xu, Ying-Qin Li, Xin-Ran Tang, Xin Wen, Qing-Mei He, Xiao-Jing Yang, Na Liu, and Jun Ma

Table of Contents

978 Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study

Jianhua Yin, Junxue Wang, Rui Pu, Haiguang Xin, Zixiong Li, Xue Han, Yibo Ding, Yan Du, Wenbin Liu, Yang Deng, Xiaowei Ji, Ming Wu, Min Yu, Hongwei Zhang, Hongyang Wang, Timothy C. Thompson, Wu Ni, and Guangwen Cao

989 Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia

Emily R. Finch, Avinash K. Kudva, Michael D. Quickel, Laura L. Goodfield, Mary J. Kennett, Jay Whelan, Robert F. Paulson, and K. Sandeep Prabhu

1000 Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of *Igf1r* That Persists Long after Parturition


Tiffany A. Katz, Serena G. Liao, Vincent J. Palmieri, Robert K. Dearth, Thushangi N. Pathiraja, Zhiguang Huo, Patricia Shaw, Sarah Small, Nancy E. Davidson, David G. Peters, George C. Tseng, Steffi Oesterreich, and Adrian V. Lee

 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Breast ductal in situ carcinoma (DCIS) accounts for approximately 20% of all breast neoplasms, but its treatment is still controversial. Large randomized phase III trials are difficult to conduct, and new efficient clinical trial models are needed to accelerate drug discovery, particularly for HER2-positive DCIS. The oral antidiabetic drug metformin has been associated with lower breast cancer risk in epidemiological studies and has shown antitumor activity in HER2-positive preclinical models. In this randomized trial, proliferation of intraepithelial lesions surrounding breast cancer was assessed in 200 patients who received metformin or placebo for 28 days prior to surgery. Upon surgery, specimens of cancer-adjacent, unaffected tissue were screened for intraepithelial lesions and characterized by immunohistochemistry. Overall, metformin did not affect proliferation in premalignant disorders. However, proliferation of HER2-positive DCIS lesions was significantly lower in women allocated to metformin relative to placebo, especially when ER was coexpressed, providing the background for an adjuvant trial incorporating metformin in HER2-positive DCIS. The micrograph shown on the cover (40× magnification) is stained for HER2 (membranous, brown) and Ki-67 (nuclear, violet) in a representative case of a grade 2 DCIS (upper left hand side) adjacent to a grade 3 ductal invasive carcinoma (lower right hand side). The DCIS component shows intense, circumferential membranous staining for HER2 in most cells, 14% of which coexpress Ki-67. The invasive tumor shows incomplete, faint HER2 and high Ki-67 staining. See the article by DeCensi *et al.* (beginning on page 888) for more information.



Cancer Prevention Research

8 (10)

Cancer Prev Res 2015;8:879-1009.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/8/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/8/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.